600196 复星医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.7797.0225.9605.2878.906
总资产报酬率 ROA (%)0.7172.8382.3992.1633.722
投入资产回报率 ROIC (%)0.9103.6183.0562.7584.844

边际利润分析
销售毛利率 (%)49.70150.07447.97447.83747.284
营业利润率 (%)13.65412.55010.3377.98910.595
息税前利润/营业总收入 (%)15.68415.03912.85610.26311.881
净利润/营业总收入 (%)10.71810.1968.5536.9938.981

收益指标分析
经营活动净收益/利润总额(%)39.84630.79640.0473.53756.954
价值变动净收益/利润总额(%)57.34267.32247.69894.18141.087
营业外收支净额/利润总额(%)-1.314-2.276-1.819-1.315-1.799

偿债能力分析
流动比率 (X)0.9280.9290.9211.0011.059
速动比率 (X)0.7640.7570.7270.7780.853
资产负债率 (%)48.22248.49048.97550.10449.508
带息债务/全部投入资本 (%)38.72638.01237.96038.27337.447
股东权益/带息债务 (%)131.164135.483135.770133.295142.559
股东权益/负债合计 (%)82.88283.72982.15580.35584.031
利息保障倍数 (X)7.1065.4324.7544.3178.066

营运能力分析
应收账款周转天数 (天)84.13074.81768.35766.22655.771
存货周转天数 (天)109.102116.923124.656120.19495.983